OncoMatch/Clinical Trials/NCT06938321
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Is NCT06938321 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including AK112 and AK130 for biliary tract cancer.
Treatment: AK112 · AK130 — There're 2 parts in this interventional study: 1. The goal of phase Ib trial is to evaluate the safety and tolerability of AK130 in combination with AK112 therapy for the purpose of observing the incidence of dose limit toxicity (DLT) as well as the confirmation of maximum tolerable dose (MTD) in the treatment of advanced biliary tract cancer (BTC), so as to determine the recommended phase 2 dose (RP2D) in the second part of the trial. 2. The goal of phase II trial is to evaluate the safety and efficacy of AK112 in combination with AK130 therapy or monotherapy in the treatment of advanced BTC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cholangiocarcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — first-line
treatment failure following prior first-line systemic therapy
Cannot have received: immunotherapy targeting immune mechanisms other than PD-1/PD-L1 inhibitors
Prior administration of any immunotherapy targeting immune mechanisms other than PD-1/PD-L1 inhibitors
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Has adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify